Seniors won’t have to pay more than $35 per month for insulin if their Medicare prescription drug plans choose to participate in a Trump administration savings model announced Wednesday.
About 3.3 million Medicare beneficiaries use insulin and pay an average of $642 per year. The Centers for Medicare & Medicaid Services’ project is estimated to save the federal government $250 million over the next five years, and save beneficiaries an average of $446 per year, according to an agency statement.
This model “provides an innovative market-driven approach that removes barriers to lower insulin costs. We call on health insurance plans ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.